化合物CT52923 T60226

Product Introduction
Bioactivity


英文名: CT52923

描述: CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.

体外活性: CT52923 inhibits PDGFRs and stem cell factor receptors with IC50 values of 100 to 200 nM. CT52923（0.01-30 μ M； 24 h) blocks smooth muscle cell migration or fibroblast proliferation induced by platelet-derived growth factor, IC50 is 64 and 280 nM respectively [1].

体内活性: CT52923 (oral; 5,15,30 and 50 mg/kg; twice daily) significantly inhibits the formation of neointima after carotid artery injury in rats [1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 60 mg/mL (128.33 mM)


关键字: CT 52923 | CT-52923 | CT52923

相关产品: AG-1478 | Regorafénib N-oxyde (M2) | Ilorasertib | Eupatolide | Axitinib | SU14813 | Regorafenib Hydrochloride | SU4312 | Multi-kinase inhibitor 1 | ON123300

相关库: Anti-Cancer Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Anti-Lung Cancer Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | Bioactive Compound Library

化合物CT52923 T60226信息由TargetMol中国为您提供，如您想了解更多关于化合物CT52923 T60226报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途